DGIdb - FLUOXETINE Drug Record

FLUOXETINE chembl:CHEMBL41 Approved

Alternate Names:

NSC-283480
FLUOXETINE
SYMBYAX
SARAFEM
PROZAC
PROZAC®
chemidplus:54910-89-3
rxcui:4493
chembl:CHEMBL41
pubchem.compound:3386
drugbank:00472

Drug Info:

Year of Approval	1987
Drug Class	antidepressive agents, second-generation
Drug Indications	antidepressant,for treatment of bipolar disorder
Drug Indications	for treatment of autism
FDA Approval	approved
Drug Class	Small molecule
Drug Indications	antidepressant
FDA Approval	not approved
Drug Class	Small Molecule
Drug Indications	for treatment of sleep apnea

(4 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
Gobbi et al., 1997, Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats., Naunyn Schmiedebergs Arch. Pharmacol.
Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry
Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology
Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport
Gören et al., 2007, Fluoxetine partly exerts its actions through GABA: a neurochemical evidence., Neurochem. Res.
Sanders et al., 2007, Chronic blockade or constitutive deletion of the serotonin transporter reduces operant responding for food reward., Neuropsychopharmacology
Tatsumi et al., 1997, Pharmacological profile of antidepressants and related compounds at human monoamine transporters., Eur. J. Pharmacol.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Mirza et al., 2007, Serotonin transporter density and anxiolytic-like effects of antidepressants in mice., Prog. Neuropsychopharmacol. Biol. Psychiatry
Richman et al., 2007, Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation., Epilepsy Res.
Iceta et al., 2007, Effect of long-term fluoxetine treatment on the human serotonin transporter in Caco-2 cells., Life Sci.
Ranganathan et al., 2001, Mutations in the Caenorhabditis elegans serotonin reuptake transporter MOD-5 reveal serotonin-dependent and -independent activities of fluoxetine., J. Neurosci.
Gassó P et al., 2017, Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine., Prog Neuropsychopharmacol Biol Psychiatry
Thomas D et al., 2002, The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels., J Pharmacol Exp Ther
Rajamani S et al., 2006, Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine., Br J Pharmacol
Chiu et al., 2004, Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels., J. Pharmacol. Sci.
Yang Z et al., 2012, Association of APC and REEP5 gene polymorphisms with major depression disorder and treatment response to antidepressants in a Han Chinese population., Gen Hosp Psychiatry
Tsai SJ et al., 2008, Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response., Pharmacogenet Genomics
Ha et al., 2006, Fluoxetine increases the nitric oxide production via nuclear factor kappa B-mediated pathway in BV2 murine microglial cells., Neurosci. Lett.
Tsai SJ et al., 2008, Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder., Pharmacogenomics J
Liu Z et al., 2007, Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders., Neurosci Lett
Bahramali E et al., 2016, Influence of ACE gene on differential response to sertraline versus fluoxetine in patients with major depression: a randomized controlled trial., Eur J Clin Pharmacol
Uz et al., 2005, Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum., Neuroscience
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Zou YF et al., 2010, Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders., Neurosci Lett
Binder EB et al., 2004, Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment., Nat Genet
Zou YF et al., 2010, Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients., Neuropsychobiology
Gassó P et al., 2014, Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients., Pharmacogenomics J
Huang X et al., 2013, ABCB6, ABCB1 and ABCG1 genetic polymorphisms and antidepressant response of SSRIs in Chinese depressive patients., Pharmacogenomics
Uhr M et al., 2008, Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression., Neuron
Di Benedetto et al., 2007, Alterations of CREB and DARPP-32 phosphorylation following cocaine and monoaminergic uptake inhibitors., Brain Res.
Lauterio et al., 1993, Fluoxetine induced insulin-like growth factor II (IGF-II) changes in hypothalami of normal, exercised and food restricted rats., Regul. Pept.
Hong CJ et al., 2006, Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder., Pharmacogenomics J

FLUOXETINE PPP1R1B

Interaction Score: 2.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17125745

Sources:
NCI
FLUOXETINE AANAT

Interaction Score: 1.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15994025

Sources:
NCI
FLUOXETINE REEP5

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
FLUOXETINE SRP19

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22795047

Sources:
PharmGKB
FLUOXETINE TPH1

Interaction Score: 1.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23733030 23221997 19590397

Sources:
PharmGKB
FLUOXETINE FKBP5

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20709156 15565110

Sources:
PharmGKB
FLUOXETINE CRHR1

Interaction Score: 0.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17258395

Sources:
PharmGKB
FLUOXETINE SLC6A4

Interaction Score: 0.48

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

Trial Name NPL-2008, Fluoxetine

Trial Name fluoxetine HCl,Prozac

PMIDs:
17486443 17356573 9537821 11752352 17335951 17215106 17289086 11487610

Sources:
TdgClinicalTrial NCI TEND
FLUOXETINE IGF2

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8265809

Sources:
NCI
FLUOXETINE SERPINE1

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18794724

Sources:
PharmGKB
FLUOXETINE NOS2

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16413968

Sources:
NCI
FLUOXETINE HTR4

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9228186

Sources:
NCI
FLUOXETINE HTR1B

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28025020

Sources:
PharmGKB
FLUOXETINE HTR1A

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19590397 16302021

Sources:
PharmGKB
FLUOXETINE GSK3B

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18195729

Sources:
PharmGKB
FLUOXETINE ACE

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27262302

Sources:
PharmGKB
FLUOXETINE BDNF

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20016225

Sources:
PharmGKB
FLUOXETINE CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
FLUOXETINE ABCB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24663076 24192121 18215618

Sources:
PharmGKB
FLUOXETINE KCNH2

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
11805215 16967046 15272206

Sources:
PharmGKB
FLUOXETINE HTR2A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name NPL-2008, Fluoxetine

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial
FLUOXETINE DRD1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FLUOXETINE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC FDA
FLUOXETINE ATXN2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
FLUOXETINE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
FLUOXETINE CYP3A4

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21393461

Sources:
DTC PharmGKB
FLUOXETINE AR

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TdgClinicalTrial: FLUOXETINE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications for treatment of sleep apnea

Drug Class Small Molecule

FDA Approval not approved

Publications:
TEND: FLUOXETINE
- Version: 01-August-2011
Alternate Names:

Drug Info:

Drug Class antidepressive agents, second-generation

Year of Approval 1987

Publications:

NCI: FLUOXETINE

Version: 14-September-2017

Alternate Names:

C506 NCI drug code

Drug Info:

Publications:

Gobbi et al., 1997, Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats., Naunyn Schmiedebergs Arch. Pharmacol.

Uz et al., 2005, Effect of fluoxetine and cocaine on the expression of clock genes in the mouse hippocampus and striatum., Neuroscience

Lauterio et al., 1993, Fluoxetine induced insulin-like growth factor II (IGF-II) changes in hypothalami of normal, exercised and food restricted rats., Regul. Pept.

DTC: FLUOXETINE

Version: 02-September-2020

Alternate Names:

CHEMBL41 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos

PharmGKB: fluoxetine

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Illi A et al., 2009, 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression., Neuroreport

Arias B et al., 2013, TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression., Neuropsychobiology

Niitsu T et al., 2013, Pharmacogenetics in major depression: a comprehensive meta-analysis., Prog Neuropsychopharmacol Biol Psychiatry

TTD: Fluoxetine
- Version: 2020.06.01
Alternate Names:

D0TR5X TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL41
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
FDA: Fluoxetine
- Version: 04-September-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)
Trial Name	NPL-2008, Fluoxetine
Trial Name	fluoxetine HCl,Prozac

Trial Name	NPL-2008, Fluoxetine
Novel drug target	Established target

FLUOXETINE Drug Record

FLUOXETINE chembl:CHEMBL41 Approved

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17125745

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15994025

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22795047

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23733030 23221997 19590397

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20709156 15565110

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17258395

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac) Trial Name NPL-2008, Fluoxetine Trial Name fluoxetine HCl,Prozac

PMIDs: 17486443 17356573 9537821 11752352 17335951 17215106 17289086 11487610

Sources: TdgClinicalTrial NCI TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 8265809

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18794724

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16413968

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9228186

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28025020

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19590397 16302021

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18195729

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27262302

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20016225

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24663076 24192121 18215618

Interaction Types & Directionality:

n/a

PMIDs:
17125745

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15994025

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
22795047

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23733030 23221997 19590397

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20709156 15565110

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17258395

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

Trial Name NPL-2008, Fluoxetine

Trial Name fluoxetine HCl,Prozac

PMIDs:
17486443 17356573 9537821 11752352 17335951 17215106 17289086 11487610

Sources:
TdgClinicalTrial NCI TEND

Interaction Types & Directionality:

n/a

PMIDs:
8265809

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18794724

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16413968

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9228186

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
28025020

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
19590397 16302021

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18195729

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27262302

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20016225

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24663076 24192121 18215618

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
11805215 16967046 15272206

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name NPL-2008, Fluoxetine

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
22931300

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21393461

Sources:
DTC PharmGKB